In the BioHarmony Drug Report Database

"Preview" Icon

Clonidine

Catapres-tts, Clonidine, Nexiclon (clonidine) is a small molecule pharmaceutical. Clonidine was first approved as Catapres-tts on 1984-10-10. It is used to treat attention deficit disorder with hyperactivity, diarrhea, dysmenorrhea, glaucoma, and hot flashes amongst others in the USA. The pharmaceutical is active against alpha-2A adrenergic receptor and alpha-2B adrenergic receptor. In addition, it is known to target potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2, potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1, alpha-2C adrenergic receptor, solute carrier family 22 member 1, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, alpha-1D adrenergic receptor, and ORF1a polyprotein;ORF1ab polyprotein. Catapres-tts’s patent is valid until 2031-09-08 (FDA).

 

Trade Name

 

Catapres-tts, Clonidine, Nexiclon
 

Common Name

 

clonidine
 

ChEMBL ID

 

CHEMBL134
 

Indication

 

attention deficit disorder with hyperactivity, diarrhea, dysmenorrhea, glaucoma, hot flashes, hypertension, intractable pain, muscle spasticity, nervous system alcohol-induced disorders, sialorrhea, substance withdrawal syndrome, tourette syndrome
 

Drug Class

 

Image (chem structure or protein)

Clonidine structure rendering